B. Riley Securities Precision Oncology and Radiopharma Conference was held on February 28th at the Lotte New York Palace. The B Riley Healthcare Equity Research team including Mayank Mamtani, Kalpit Patel, Yuan Zhi, Ph.D., Brandon Carney, Hsuan-Cheng (Kevin) Kuo and Jie Li brought together 32 cutting-edge SMID-cap public/private companies for a multi-track event featuring ten panel discussions, six fireside chats as well as partnering and 1x1 investor meetings.
We would like to thank our panelists for contributing their time and insights into a range of topics including: AI-Driven Solutions Focused on Optimizing Oncology Drug Development, Radioimaging Resurge? — Exploring the Commercial Potential in the Next Wave of Diagnostic Innovations, Mastering Mutations and Rewiring Pathways to Crack Pancreatic Cancer, Radiopharma in 2025 — Challenges/Opportunities in Radiopharma Value Chain, Unlocking the Full Potential of Nectin-4 Targeting Therapies, Engineering the Future of Cancer with ADCs, Bispecifics, & TCEs, What It Takes To Move the Needle in Improving Durable Responses in Colorectal Cancer?, Case Study of Pb212: Considerations to Deliver Clinical Efficacy; and last but not the least, Healthcare Policy Disruptions In the Making featuring our conference keynote speakers.
Dan Schmitt, CEO, Actuate Therapeutics Inc. (ACTU)
Andrew Adamovich, CEO, Advancell (Private)
Matthew Vincent, CBO, Advancell (Private)
Robin Taylor, CCO, Agenus (AGEN)
Art Hogan, Managing Director and Chief Market Strategist, B. Riley Financial
Mark Erlander, Ph.D., CEO, Cardiff Oncology (CRDF)
Peter Pitts, President, Center for Medicine in the Public Interest, Former Associate Commissioner, US Food and Drug Administration
Claudio D'Ambrosio, CRO, ConcertAI
Jeff Elton, CEO, ConcertAI
Martin Lehr, CEO, Context Therapeutics (CNTX)
Yuval Cohen, CEO, of Corbus Pharmaceuticals (CRBP)
Kirsten Axelsen, Senior Policy Advisor, DLA Piper, non-resident fellow American Enterprise Institute
Ian Jenkins, CSO, GATC Health
Larry (Lei) Xiao, CEO, Innovative Cellular Therapeutics (Private)
John Wiggins, Vice President Isotope Strategy, Lantheus (LNTH)
Scott Koenig, President & CEO Macrogenics (MGNX)
Avik Roy, President and CEO of NIHCM LLC and NIHCM Foundation; President of the Foundation for Research on Equal Opportunity (FREOPP)
Jeremy Castle, COO, The Oncology Institute (TOI)
Yale D. Podnos, CMO, The Oncology Institute (TOI)
Thijs Spoor, CEO, Perspective Therapeutics (CATX)
Amos Hedt, CBO, Perspective Therapeutics (CATX)
Etienne Montagut, President, Pharmalogic (Private)
Riccardo Canevari, CEO, of Radiopharm Theranostics (RADX)
Christian Behrenbruch, CEO, Telix Pharmaceuticals, Inc. (TLX)
John L. Sullivan, Venture Partner, Two Bear Capital
Jonathan Pachter, CSO, Verastem Oncology (VSTM)
Ingmar Bruns,CMO, Zentalis (ZNTL)
Lucas Donigian, VP Business & Commercial Development, Zymeworks (ZYME)
B. Riley Securities
Varied